Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
As this year’s #MDSCongress draws to a close, it’s important to reflect on the unmet needs of people living with neurodegenerative diseases such as #ProgressiveSupranuclearPalsy and #Parkinsons. Learn more about UCB’s work to support earlier diagnosis: ht
— UCB News (@ucb_news) 16.09.2020 -
Visit https://t.co/33gbJ56QXW to learn more about the #AdvantageHers campaign and @CaroWozniacki's unique rheumatoid arthritis story. https://t.co/yP0449Eafm
— UCB News (@ucb_news) 15.09.2020 -
Diagnosis is a key focus at #MDSCongress. UCB are working with Prof. Antoniades and her team @UniofOxford @Neurometrology @NDCNOxford, on how wearable tech may help to differentiate #ProgressiveSupranuclearPalsy diagnosis from #Parkinsons: https://t.co/T
— UCB News (@ucb_news) 15.09.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
